Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Practice Current
  • Practice Buzz

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Clinical Practice
Home
A peer-reviewed clinical neurology journal for the practicing neurologist
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Practice Current
  • Practice Buzz

Share

October 19, 2020Research

Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy

Alisha Jamil, Noah Levinson, View ORCID ProfileMichael Gelfand, Chloe E. Hill, View ORCID ProfilePouya Khankhanian, View ORCID ProfileKathryn A. Davis
First published October 19, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000992
Alisha Jamil
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noah Levinson
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Gelfand
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Gelfand
Chloe E. Hill
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pouya Khankhanian
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pouya Khankhanian
Kathryn A. Davis
Department of Medicine (AJ), University of Pennsylvania; Department of Neurology (NL), Temple University, PA; Department of Neurology (MG, PK, KAD), University of Pennsylvania, Philadelphia; Department of Neurology (CEH), University of Michigan, Ann Arbor; and Center for Neuroengineering and Therapeutics (KAD), University of Pennsylvania, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kathryn A. Davis
Full PDF
Citation
Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy
Alisha Jamil, Noah Levinson, Michael Gelfand, Chloe E. Hill, Pouya Khankhanian, Kathryn A. Davis
Neurol Clin Pract Oct 2020, 10.1212/CPJ.0000000000000992; DOI: 10.1212/CPJ.0000000000000992

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
24

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objectives To evaluate the effectiveness and tolerability of clobazam as an adjunctive treatment for adults with drug-resistant epilepsy.

Methods We performed a single-center, retrospective chart review of patients ≥18 years of age with drug-resistant epilepsy who started clobazam between 2010 and 2018. Included patients had outpatient visits both before and ≥1 month after clobazam initiation. Epilepsy classification, seizure frequency before and after clobazam, duration of clobazam treatment, and adverse effects were analyzed.

Results A total of 417 patients met inclusion criteria. Mean age was 37.5 years, and 54% of patients were female. Patients were on a mean of 2.4 antiepileptic drugs at time of initiation of clobazam. Epilepsy types were focal (56.8%), Lennox-Gastaut syndrome (LGS) (21.1%), generalized (15.1%), and unclassified (7.0%). At the first follow-up visit ≥1 month after clobazam initiation, 50.3% of patients had >50% reduction in seizure frequency, and 20.5% were seizure-free. Of the initial cohort, 17.1% were followed >1 year and were seizure-free at last follow-up. Response rates did not differ between different epilepsy classifications. Fifty-one percent of patients experienced ≥1 side effect, most commonly lethargy/fatigue (30.7%) or mood changes (10.8%). A total of 178 (42.6%) patients discontinued clobazam, most commonly due to adverse effects (55%).

Conclusions Clobazam is effective and safe as a long-term adjunctive therapy for adults with drug-resistant epilepsy; efficacy in off-label use is similar to that in LGS.

Classification of evidence This study provides Class IV evidence that clobazam is an effective treatment for adults with drug-resistant epilepsy, independent of epilepsy classification.

Footnotes

  • ↵* These authors contributed equally to this work.

  • Received April 9, 2020.
  • Accepted September 30, 2020.
  • © 2020 American Academy of Neurology

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Epilepsy/Seizures
  • Antiepileptic drugs
  • Class IV
  • Generalized seizures
  • Partial seizures

Alert Me

  • Alert me when eletters are published
Neurology: Clinical Practice: 11 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Clinical Practice |  Print ISSN: 2163-0402
Online ISSN: 2163-0933

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise